Dr. Kumar on the Design of a Phase II Trial of MLN9708

Shaji K. Kumar, MD
Published Online: Wednesday, January 15, 2014
Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, describes the design of a phase II trial looking at the single-agent activity of the proteasome inhibitor MLN9708 for the treatment of patients with multiple myeloma.

In this follow-up to studies previously presented, researchers analyzed patients with relapsed multiple myeloma in order to identify potential activity. In the study, 32 patients who were pretreated with immunomodulatory drugs (90% had exposure to Revlimid ) were enrolled.

Researchers approached the trial to treat patients with the MLN9708 dose identified in the phase I study. If a prespecified degree of response was not seen after 2 or 4 cycles, dexamethasone would then be added. There is no data from the phase I study regarding the combination of MLN9708 and dexamethasone, so researchers set out to answer both questions.




Online CME Activities
Free CME from PER
Advances in the Treatment of Metastatic Colorectal Cancer
Renal Cell Carcinoma: Recent Advances, New Questions
Community Practice Connections™: Working Group to Advance the Treatment of Triple-Negative Breast Cancer: Examining the Evidence and Looking to the Future
Community Practice Connections™: 10th Annual New York Lung Cancer Symposium®
More Reading
$auto_registration$